OncoCyte Corporation (AMEX:OCX) entered into a Definitive Agreement to acquire Insight Genetics, Inc. for $18 million on January 10, 2020. The consideration consists of consisting of $7 million in cash and $5 million of OncoCyte common shares, less deductions for transaction expenses and other liabilities. OncoCyte may pay contingent consideration of up to $6 million, in any combination of cash or OncoCyte common shares if certain milestones are achieved. The closing of the merger with IG is subject to a number of conditions, including approval of the merger by IG’s stockholders.